Latest Indonesia News

Recce Pharmaceuticals has locked in a non-dilutive A$30 million debt facility with Avenue Capital Group, extending its cash runway to support pivotal Phase 3 trials and commercialisation of its synthetic anti-infective R327G.

VBX Limited is set to raise $10 million through an initial public offering to fund the development of its Wuudagu Bauxite Project in Western Australia, supported by a positive pre-feasibility study and strong market fundamentals driven by China’s growing aluminium demand.

BPH Global Ltd has completed its second seaweed sale under a strategic partnership in Indonesia, marking steady progress in its supply network expansion and operational execution.

Cokal Limited has secured US$15 million in strategic debt funding to ramp up metallurgical coal production at its BBM mine, while terminating all agreements with Cratus due to non-performance.

Austin Engineering has raised its FY25 revenue guidance to $370 million, driven by strong growth in the Americas, but has lowered its EBIT forecast due to operational challenges in Chile.

Far East Gold has commenced a 36-hole diamond drilling program at its Idenburg Gold Project in Papua, aiming to expand its current 540,000oz inferred resource and validate a multi-million-ounce exploration target.

Ovanti Limited is set to raise approximately $1 million through a two-tranche share placement to support its US buy now, pay later expansion and ongoing legal matters.

Recce Pharmaceuticals has completed a A$15.8 million capital raise to fund pivotal Phase 3 clinical trials and progress its FDA application, positioning the company for potential commercial breakthroughs in antibiotic-resistant infections.

TruScreen Group Limited has announced a capital raising initiative involving Placement and Share Purchase Plan (SPP) Options, aiming to secure approximately NZ$3 million to fund strategic growth and working capital needs. The offer, subject to shareholder approval, includes up to 80.9 million Placement Options and 55.5 million SPP Options exercisable at A$0.02.

TruScreen Ordinary Shares Group Limited has announced a combined share purchase plan and placement to raise approximately NZD 1.78 million, aiming to accelerate its international expansion and cervical cancer screening initiatives.

TruScreen Group Limited has launched a NZ$1.22 million Share Purchase Plan offering discounted shares to eligible investors, aiming to fuel growth in key international markets and public health initiatives.

TruScreen Group Limited forecasts a robust 64% increase in FY26 sales, driven by strategic market expansions and new distribution agreements. The company’s AI-enabled cervical cancer screening technology is gaining traction across emerging markets.